(51) International Patent Classification ^{6} : C07K 14/605, 14/00, A61K 38/00, 38/26	**A1**	(11) International Publication Number: **WO 98/08873** (43) International Publication Date: 5 March 1998 (05.03.98)

(21) International Application Number: PCT/US97/15042

(22) International Filing Date: 26 August 1997 (26.08.97)

(30) Priority Data:
60/024,982   30 August 1996 (30.08.96)   US
Not furnished   21 August 1997 (21.08.97)   US

(71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventor: EFENDIC, Suad; Stjarnvagen 16B, S-181 34 Lidingo (SE).

(74) Agent: STEVENSON, Robert, W.; Brinks Hofer Gilson & Lione, NBC Tower, Suite 3600, 455 North Cityfront Plaza Drive, Chicago, IL 60611-5599 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY

(57) Abstract

This invention provides a method of attenuating post-surgical catabolic changes and hormonal responses to stress. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

USE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) OR ANALOGS TO ABOLISH CATABOLIC CHANGES AFTER SURGERY

Background Of The Invention

5

1. Field of the Invention. This invention relates to a method of improving recovery after surgery by preventing the catabolic reaction and insulin resistance caused by surgical trauma.

10   2. Background Information. Approximately 20-25,000 surgical treatments per million inhabitants are performed annually in the western world. Surgery, like any trauma, initiates marked changes in metabolism [Shaw, J.H.F., et al., Ann. Surg., 209(1):63-72 (1989); Little, R. A., et al., Prog.

15 Clin. Biol. Res. 263A:463-475 (1987); Frayn, K.N., Clin. Endocrinol. 24:577-599 (1986); Brandi, L., et al., Clin. Sci. 85:525-35 (1993)]. Accelerated synthesis of glucose, the primary fuel of tissue repair, is an important metabolic change after surgery, and occurs at the expense of body

20 protein and energy stores [Gump, F.E., et al., J. Trauma, 14:378-88 (1974); Black, R.B., et al., Ann. Surg. 196:420-35 (1982)].

These changes have previously been attributed to the gluco-regulatory stress hormones and other catabolic factors,

25 such as cytokines, that are released as a response to trauma. The more marked the change toward catabolism, the greater is the morbidity, and the slower is the recovery of the patient [Thorell, A., et al., Eur. J. Surg., 159:593-99 (1993); Chernow, B., et al., Arch. Intern. Med., 147:1273-8 (1987)].

30   Post-operative catabolic states may be treated with anabolic hormones, particularly, Growth Hormone and IGF-1 [Hammarkvist, F., et al., Ann. Surg., 216(2):184-190 (1991); Ziegler, T., et al., Annu. Rev. Med., 45:459-80 (1994); Ziegler, T.R., et al. J. Parent. Ent. Nutr. 14(6):574-81

35 (1990)]. Some studies show a clear benefit from insulin treatment in catabolic trauma patients [Hinton, P., et al., Lancet, 17(April):767-69 (1971); Shizgal, H., et al., Am. J. Clin. Nutr., 50:1355-63 (1989); Woolfson, A.M.J., et al., N.

-2-

Clin. Nutr., 50:1355-63 (1989); Woolfson, A.M.J., et al., *N.*
Engl. J. Med. 300:14-17 (1979); Brooks, D., et al., *J. Surg.*
Res. 40:395-405 (1986); Sakurai, Y., et al., *Ann. Surg.*
222:283-97 (1995)].

5   Yet other studies, however, show that the post-
operative benefits of insulin are often compromised by insulin
resistance. In insulin resistance, normal concentrations of
insulin elicit less than normal responses. Insulin resistance
may be due to a decrease in binding of insulin to cell-surface
10   receptors, or to alterations in intracellular metabolism. The
first type, characterized as a decrease in insulin
sensitivity, can typically be overcome by increased insulin
concentration. The second type, characterized as a decrease
in insulin responsiveness, cannot be overcome by large
15   quantities of insulin.

          Insulin resistance following trauma can be overcome
by doses of insulin that are proportional to the degree of
insulin resistance, and thus is apparently a decrease in
insulin sensitivity [Brandi, L.S., et al., *Clin. Science*
20   79:443-450 (1990); Henderson, A.A., et al., *Clin. Sci.* 80:25-
32 (1990)]. Reduction in insulin sensitivity following
elective abdominal surgery lasts at least five days, but not
more than three weeks, and is most profound on the first post-
operative day, and may take up to three weeks to normalize
25   [Thorell, A., et al., (1993)].

          The causes of the observed transient insulin
resistance following trauma are not well-understood. Both
cortisol and glucagon may contribute to the catabolic response
to trauma [Alberti, K.G.M.M., et al., *J. Parent. Ent. Nutr.*
30   4(2): 141-46 (1980); Gelfand, R.A., et al., *J. Clin. Invest.*
74(December):2238-2248 (1984); Marliss, E.B., et al., *J.*
Clin. Invest. 49:2256-70 (1970)]. However, studies of post-
operative insulin resistance has failed to show any
correlation between changes in these catabolic hormones and
35   changes in insulin sensitivity after surgery [Thorell, A., et
al. (1993); Thorell A., *Karolinska Hospital and Institute*, 104

-3-

01 Stockholm, Sweden (1993); Thorell, A, et al., Br. J. Surg. 81:59-63 (1994)].

Increased availability of lipids after trauma may induce insulin resistance through the glucose-fatty acid cycle
5   [Randle, P.J., et al., Diab. Metab. Rev. 4(7):623-38 (1988)]. Increased availability of free fatty acids (FFA) induced insulin resistance and changed substrate oxidation from glucose to fat, even in the presence of simultaneous infusions of insulin [Ferrannini, E., et al., J. Clin. Invest. 72: 1737-
10   47 (1983); Bevilacqua, S., et al., Metabolism 36:502-6 (1987); Bevilacqua, S., et al., Diabetes 39:383-89 (1990); Bonadonna, R.C., et al., Am. J. Physiol. 259:E736-50 (1990); Bonadonna, R.C., et al., Am. J. Physiol. 257:E49-56 (1989)].

Elective surgery is routinely performed after an
15   overnight fast to reduce risks of anesthesia. This entrenched practice of fasting the patient overnight (10-16 hours) before surgery enhances the development of the catabolic state, and worsens insulin resistance. Studies in rats undergoing stress, such as hemorrhage and endotoxemia, show that fasting
20   for periods less than 24 hours markedly affects the catabolic response to trauma [Alibegovic, A., et al., Circ. Shock, 39:1-6 (1993); Eshali, A. H., et al. Eur. J. Surg., 157:85-89 (1991); Ljungqvist, O., et al., Am. J. Physiol., 22:E692-98 (1990)]. Even a short period of fasting before the onset of a
25   trauma in rats markedly decreases carbohydrate reserves, profoundly changes the hormonal environment, increases stress response, and, most importantly, increases mortality [Alibegovic, A., et al., Circ. Shock, 39:1-6 (1993)].

Glucose administration before surgery, either orally
30   [Nygren, J., et al., Ann. Surg. 222:728-34 (1995)], or by infusion, reduces insulin resistance after surgery, compared to fasted patients. Patients who received overnight glucose infusions (5 mg/kg/min) before elective abdominal surgery lost an average of 32% of insulin sensitivity after the operation,
35   while patients, entering surgery after a routine overnight fast, lost an average of 55% of their insulin sensitivity

-4-

[Ljungqvist, O., et al., J. Am. Coll. Surg. 178:329-36 (1994)].

In addition to the adverse effects of fasting on recovery from surgery, immobilization of the patient and
5 hypocaloric nutrition during and after surgery also increase insulin resistance after surgery. In healthy subjects, 24 hours of immobilization and hypocaloric nutrition have been shown to induce a 20-30% increase in peripheral insulin resistance in healthy volunteers. Thus, postoperative insulin
10 resistance previously reported after pre-operative glucose infusions [Ljungqvist, O., (1994)] may in part be due to the additive effects of post-operative bed rest and hypocaloric nutrition.

Given the prevalence of surgery, it is important to
15 minimize negative side-effects, such as catabolic response and insulin resistance, in order to improve healing and to reduce mortality. Post-operative insulin resistance frustrates treatment of the catabolic state with insulin. The entrenched medical practice of pre-operative fasting exacerbates post-
20 operative catabolic state and insulin resistance. Thus, a treatment that overcomes both the catabolic state and insulin resistance is needed.

As disclosed herein, one such treatment that overcomes both the catabolic state and insulin resistance is
25 administration of glucose and insulin together before, during, and after the operation. Insulin infusion, however, creates the potential for hypoglycemia, which is defined as blood glucose below 0.3 mM. Hypoglycemia increases the risk of ventricular arrhythmia and is a dangerous consequence of
30 insulin infusion. An algorithm for insulin infusion for diabetics was developed to prevent hypoglycemia [Hendra, T.J., et al., Diabetes Res. Clin. Pract., 16:213-220 (1992)].
However, 21% of the patients developed hypoglycemia under this algorithm. In another study of glucose control following
35 myocardial infarction, 18% of the patients developed

-5-

hypoglycemia when infused with insulin and glucose [Malmberg, K.A., et al., Diabetes Care, 17:1007-1014 (1994)].

Insulin infusion also requires frequent monitoring of blood glucose levels so that the onset of hypoglycemia can
5   be detected and remedied as soon as possible. In patients receiving insulin infusion in the cited study [Malmberg, 1994], blood glucose was measured at least every second hour, and the rate of infusion adjusted accordingly. Thus, the safety and efficacy of insulin-glucose infusion therapy for
10   myocardial infarct patients depends on easy and rapid access to blood glucose data. Such an intense need for monitoring blood glucose places a heavy burden on health care professionals, and increases the inconvenience and cost of treatment. As a result, pre-surgical clinical care units
15   often do not allot resources for monitoring and optimizing blood glucose levels before surgery, such as might be obtained by intravenous administration of insulin. Considering the risks and burdens inherent in insulin infusion, an alternate approach to pre/post-surgery control of catabolic reaction to
20   trauma is needed.

The incretin hormone, glucagon-like peptide 1, abbreviated as GLP-1, is processed from proglucagon in the gut and enhances nutrient-induced insulin release [Krcymann B., et al., Lancet 2:1300-1303 (1987)]. Various truncated forms of
25   GLP-1, are known to stimulate insulin secretion (insulinotropic action) and cAMP formation [see, e g., Mojsov, S., Int. J. Peptide Protein Research, 40:333-343 (1992)]. A relationship between various in vitro laboratory experiments and mammalian, especially human, insulinotropic responses to
30   exogenous administration of GLP-1, GLP-1(7-36) amide, and GLP-1(7-37) acid has been established [see, e.g., Nauck, M.A., et al., Diabetologia, 36:741-744 (1993); Gutniak, M., et al., New England J. of Medicine, 326(20):1316-1322 (1992); Nauck, M.A., et al., J. Clin. Invest., 91:301-307 (1993); and Thorens, B.,
35   et al., Diabetes, 42:1219-1225 (1993)]. GLP-1(7-36) amide exerts a pronounced antidiabetogenic effect in insulin-dependent diabetics by stimulating insulin sensitivity and by

-6-

enhancing glucose-induced insulin release at physiological concentrations [Gutniak M., et al., *New England J. Med.* 326:1316-1322 (1992)]. When administered to non-insulin dependent diabetics, GLP-1(7-36) amide stimulates insulin
5   release, lowers glucagon secretion, inhibits gastric emptying and enhances glucose utilization [Nauck, 1993; Gutniak, 1992; Nauck, 1993].

The use of GLP-1 type molecules for prolonged therapy has been obstructed because the serum half-life of
10   such peptides is quite short. For example, GLP-1(7-37) has a serum half-life of only 3 to 5 minutes. GLP-1(7-36) amide has a half-life of about 50 minutes when administered subcutaneously. Thus, these GLP molecules must be administered as a continuous infusion to achieve a prolonged
15   effect [Gutniak M., et al., *Diabetes Care* 17:1039-1044 (1994)]. In the present invention, GLP-1's short half-life and the consequent need for continuous administration are not disadvantages because the patient is typically hospitalized, before surgery, and fluids are continuously administered
20   parenterally before, during, and after surgery.

Summary Of The Invention

The present invention therefore presents for the first time a method of attenuating post-surgical catabolic
25   changes and insulin resistance, comprising, administering to a patient in need thereof a compound selected from the group consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof.

30   ## Brief Description of the Drawings

Figure 1 is a graph of the percent change in glucose infusion rate (GIR) in the post-operative (*postop*) clamp period relative to the pre-operative (*preop*) clamp period for six (6) control patients (O) and seven (7) patients
35   receiving a hyperinsulinemic, normoglycemic infusion (■) before and during elective surgery.

-7-

Figure 2 is a graph showing the effect of continuous infusion GLP-1 (7-36) amide on average blood glucose concentration (mM) (━━■━━) in five non-insulin dependent diabetes mellitus (NIDDM) patients during the night. The
5 graph also depicts the effect of continuous insulin infusion on average blood glucose concentration (━ ━O━ ━) in the same five NIDDM patients, but on a different night.

Figure 3 is a graph showing the effect of GLP-1 (7-36) amide infusion on average blood glucose concentration (mM)
10 (━━■━━) in five NIDDM patients when infused during the day, for three hours starting at the beginning of each of three meals. The graph also depicts the effect of subcutaneous injection of insulin on average blood glucose concentration (━ ━O━ ━) in the same five NIDDM patients, but on a different
15 day, and with injection shortly before each meal.

Detailed Description Of The Invention

"GLP-1" means GLP-1(7-37). By custom in the art, the amino-terminus of GLP-1(7-37) has been assigned number 7
20 and the carboxy-terminus, number 37. The amino acid sequence of GLP-1(7-37) is well-known in the art, but is presented below for the reader's convenience:

$$NH_2\text{-}His^7\text{-}Ala\text{-}Glu\text{-}Gly^{10}\text{-}$$
25
$$Thr\text{-}Phe\text{-}Thr\text{-}Ser\text{-}Asp^{15}\text{-}Val\text{-}Ser\text{-}Ser\text{-}Tyr\text{-}Leu^{20}\text{-}$$
$$Glu\text{-}Gly\text{-}Gln\text{-}Ala\text{-}Ala^{25}\text{-}Lys\text{-}Glu\text{-}Phe\text{-}Ile\text{-}Ala^{30}\text{-}$$
$$Trp\text{-}Leu\text{-}Val\text{-}Lys\text{-}Gly^{35}\text{-}Arg\text{-}Gly^{37}\text{-}COOH$$

(SEQ ID NO:1)

30   A "GLP-1 analog" is defined as a molecule having one or more amino acid substitutions, deletions, inversions, or additions compared with GLP-1. GLP-1 analogs known in the art include, for example, GLP-1(7-34) and GLP-1(7-35), GLP-1(7-36), Gln^9-GLP-1(7-37), D-Gln^9-GLP-1(7-37), Thr^{16}-Lys^{18}-GLP-
35 1(7-37), and Lys^{18}-GLP-1(7-37). Preferred GLP-1 analogs are

-8-

GLP-1(7-34) and GLP-1(7-35), which are disclosed in U.S.
Patent No: 5,118,666, herein incorporated by reference, and
also GLP-1(7-36), which are the biologically processed forms
of GLP-1 having insulinotropic properties. Other GLP-1
5   analogs are disclosed in U.S. Patent No. 5,545,618 which is
incorporated herein by reference.

A "GLP-1 derivative" is defined as a molecule having
the amino acid sequence of GLP-1 or of a GLP-1 analog, but
additionally having chemical modification of one or more of
10 its amino acid side groups, α-carbon atoms, terminal amino
group, or terminal carboxylic acid group. A chemical
modification includes, but is not limited to, adding chemical
moieties, creating new bonds, and removing chemical moieties.
Modifications at amino acid side groups include, without
15 limitation, acylation of lysine ε-amino groups, N-alkylation
of arginine, histidine, or lysine, alkylation of glutamic or
aspartic carboxylic acid groups, and deamidation of glutamine
or asparagine. Modifications of the terminal amino include,
without limitation, the des-amino, N-lower alkyl, N-di-lower
20 alkyl, and N-acyl modifications. Modifications of the
terminal carboxy group include, without limitation, the amide,
lower alkyl amide, dialkyl amide, and lower alkyl ester
modifications. Lower alkyl is C_1-C_4 alkyl. Furthermore, one
or more side groups, or terminal groups, may be protected by
25 protective groups known to the ordinarily-skilled protein
chemist. The α-carbon of an amino acid may be mono- or
dimethylated.

A preferred group of GLP-1 analogs and derivatives
for use in the present invention is composed of molecules of
30 the formula:

$$R_1-X-Glu-Gly^{10}-$$
Thr-Phe-Thr-Ser-Asp^{15}-Val-Ser-Ser-Tyr-Leu^{20}-
Y -Gly-Gln-Ala-Ala^{25}-Lys- Z -Phe-Ile-Ala^{30}-
Trp-Leu-Val-Lys-Gly^{35}-Arg-R$_2$

35   (SEQ ID NO:2)

and the pharmaceutically-acceptable salts thereof, wherein: R_1 is selected from the group consisting of L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine, and

5   alpha-methyl-histidine; X is selected from the group consisting of Ala, Gly, Val, Thr, Ile, and alpha-methyl-Ala; Y is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly; Z is selected from the group consisting of Glu, Gln, Ala, Thr, Ser, and Gly; and R_2 is selected from the group

10   consisting of NH_2, and Gly-OH; provided that the compound has an isoelectric point in the range from about 6.0 to about 9.0 and further providing that when R_1 is His, X is Ala, Y is Glu, and Z is Glu, R_2 must be NH_2.

Numerous GLP-1 analogs and derivatives having an

15   isoelectric point in this range have been disclosed and include, for example:

GLP-1 (7-36)NH_2

Gly^8-GLP-1 (7-36)NH_2

Gln^9-GLP-1 (7-37)

20   D-Gln^9-GLP-1 (7-37)

acetyl-Lys^9-GLP-1 (7-37)

Thr^9-GLP-1 (7-37)

D-Thr^9-GLP-1 (7-37)

Asn^9-GLP-1 (7-37)

25   D-Asn^9-GLP-1 (7-37)

Ser^{22}-Arg^{23}-Arg^{24}-Gln^{26}-GLP-1 (7-37)

Thr^{16}-Lys^{18}-GLP-1 (7-37)

Lys^{18}-GLP-1 (7-37)

Arg^{23}-GLP-1 (7-37)

30   Arg^{24}-GLP-1 (7-37), and the like [see, e.g., WO 91/11457].

Another preferred group of active compounds for use in the present invention is disclosed in WO 91/11457, and consists essentially of GLP-1(7-34), GLP-1(7-35), GLP-1(7-36),

35   or GLP-1(7-37), or the amide form thereof, and

-10-

pharmaceutically-acceptable salts thereof, having at least one
modification selected from the group consisting of:

      (a) substitution of glycine, serine, cysteine,
threonine, asparagine, glutamine, tyrosine, alanine, valine,
5 isoleucine, leucine, methionine, phenylalanine, arginine, or
D-lysine for lysine at position 26 and/or position 34; or
substitution of glycine, serine, cysteine, threonine,
asparagine, glutamine, tyrosine, alanine, valine, isoleucine,
leucine, methionine, phenylalanine, lysine, or a D-arginine
10 for arginine at position 36;

      (b) substitution of an oxidation-resistant amino
acid for tryptophan at position 31;

      (c) substitution of at least one of: tyrosine for
valine at position 16; lysine for serine at position 18;
15 aspartic acid for glutamic acid at position 21; serine for
glycine at position 22; arginine for glutamine at position 23;
arginine for alanine at position 24; and glutamine for lysine
at position 26; and

      (d) substitution of at least one of: glycine,
20 serine, or cysteine for alanine at position 8; aspartic acid,
glycine, serine, cysteine, threonine, asparagine, glutamine,
tyrosine, alanine, valine, isoleucine, leucine, methionine, or
phenylalanine for glutamic acid at position 9; serine,
cysteine, threonine, asparagine, glutamine, tyrosine, alanine,
25 valine, isoleucine, leucine, methionine, or phenylalanine for
glycine at position 10; and glutamic acid for aspartic acid at
position 15; and

      (e) substitution of glycine, serine, cysteine,
threonine, asparagine, glutamine, tyrosine, alanine, valine,
30 isoleucine, leucine, methionine, or phenylalanine, or the D-
or N-acylated or alkylated form of histidine for histidine at
position 7; wherein, in the substitutions is (a), (b), (d),
and (e), the substituted amino acids can optionally be in the
D-form and the amino acids substituted at position 7 can
35 optionally be in the N-acylated or N-alkylated form.

      Because the enzyme, dipeptidyl-peptidase IV (DPP
IV), may be responsible for the observed rapid *in vivo*

-11-

inactivation of administered GLP-1, [see, e.g., Mentlein, R., et al., *Eur. J. Biochem.*, 214:829-835 (1993)], administration of GLP-1 analogs and derivatives that are protected from the activity of DPP IV is preferred, and the administration of

5   Gly^8-GLP-1(7-36)NH_2, Val^8-GLP-1(7-37)OH, a-methyl-Ala^8-GLP-1(7-36)NH_2, and Gly^8-Gln^{21}-GLP-1(7-37)OH, or pharmaceutically-acceptable salts thereof, is more preferred.

The use in the present invention of a molecule claimed in U.S. Patent No. 5,188,666, which is expressly

10 incorporated by reference, is preferred. Such molecule is selected from the group consisting of a peptide having the amino acid sequence:

NH_2-His^7-Ala-Glu-Gly^{10}-
Thr-Phe-Thr-Ser-Asp^{15}-Val-Ser-Ser-Tyr-Leu^{20}-
15   Glu-Gly-Gln-Ala-Ala^{25}-Lys-Glu-Phe-Ile-Ala^{30}-
Trp-Leu-Val-X

(SEQ ID NO:3)

wherein X is selected from the group consisting of Lys and

20 Lys-Gly; and a derivative of said peptide, wherein said peptide is selected from the group consisting of: a pharmaceutically-acceptable acid addition salt of said peptide; a pharmaceutically-acceptable carboxylate salt of said peptide; a pharmaceutically-acceptable lower alkylester

25 of said peptide; and a pharmaceutically-acceptable amide of said peptide selected from the group consisting of amide, lower alkyl amide, and lower dialkyl amide.

Another preferred group of molecules for use in the present invention consists of compounds, claimed in U.S.

30 Patent No. 5,512,549, which is expressly incorporated herein by reference, of the general formula:

-12-

$$R^1\text{-Ala-Glu-Gly}^{10}\text{-}$$
$$\text{Thr-Phe-Thr-Ser-Asp}^{15}\text{-Val-Ser-Ser-Tyr-Leu}^{20}\text{-}$$
$$\text{Glu-Gly-Gln-Ala-Ala}^{25}\text{-Xaa-Glu-Phe-Ile-Ala}^{30}\text{-}$$
$$\text{Trp-Leu-Val-Lys-Gly}^{35}\text{-Arg-R}^3$$
$$|$$
$$R^2$$

(SEQ ID NO:4)

and pharmaceutically-acceptable salts thereof, wherein R^1 is selected from the group consisting of 4-imidazopropionyl, 4-imidazoacetyl, or 4-imidazo-α,α dimethyl-acetyl; R^2 is selected from the group consisting of C_6-C_{10} unbranched acyl, or is absent; R^3 is selected from the group consisting of Gly-OH or NH_2; and, Xaa is Lys or Arg, may be used in present invention.

More preferred compounds of SEQ ID NO:4 for use in the present invention are those in which Xaa is Arg and R^2 is C_6-C_{10} unbranched acyl.

Highly preferred compounds of SEQ ID NO:4 for use in the present invention are those in which Xaa is Arg, R^2 is C_6-C_{10} unbranched acyl, and R^3 is Gly-OH.

More highly preferred compounds of SEQ ID NO:4 for use in the present invention are those in which Xaa is Arg, R^2 is C_6-C_{10} unbranched acyl, R^3 is Gly-OH, and R^1 is 4-imidazopropionyl.

The most preferred compound of SEQ ID NO:4 for use in the present invention is that in which Xaa is Arg, R^2 is C_8 unbranched acyl, R^3 is Gly-OH, and R^1 is 4-imidazopropionyl.

The use in the present invention of a molecule claimed in U.S. Patent No. 5,120,712, which is expressly incorporated by reference, is highly preferred. Such molecule is selected from the group consisting of a peptide having the amino acid sequence:

$$NH_2-His^7-Ala-Glu-Gly^{10}-$$
$$Thr-Phe-Thr-Ser-Asp^{15}-Val-Ser-Ser-Tyr-Leu^{20}-$$
$$Glu-Gly-Gln-Ala-Ala^{25}-Lys-Glu-Phe-Ile-Ala^{30}-$$
$$Trp-Leu-Val-Lys-Gly^{35}-Arg-Gly^{37}-COOH$$

5

(SEQ ID NO:1)

and a derivative of said peptide, wherein said peptide is
selected from the group consisting of: a pharmaceutically-
acceptable acid addition salt of said peptide; a
10   pharmaceutically-acceptable carboxylate salt of said peptide;
a pharmaceutically-acceptable lower alkylester of said
peptide; and a pharmaceutically-acceptable amide of said
peptide selected from the group consisting of amide, lower
alkyl amide, and lower dialkyl amide.
15   The use of GLP-1(7-36) amide, or a pharmaceutically-
acceptable salt thereof, in the present invention is most
highly preferred. The amino acid sequence of GLP-1(7-36)
amide is:

$$NH_2-His^7-Ala-Glu-Gly^{10}-$$
20
$$Thr-Phe-Thr-Ser-Asp^{15}-Val-Ser-Ser-Tyr-Leu^{20}-$$
$$Glu-Gly-Gln-Ala-Ala^{25}-Lys-Glu-Phe-Ile-Ala^{30}-$$
$$Trp-Leu-Val-Lys-Gly^{35}-Arg-NH_2$$

(SEQ ID NO:5)
25   Methods for preparing the active compound used in
the present invention, namely, GLP-1, an GLP-1 analog, or a
GLP-1 derivative used in the present invention are well-known,
and are described in U.S. Patent Nos. 5,118,666, 5,120,712,
and 5,523,549, which are incorporated by reference.
30   The amino acid portion of the active compound used
in the present invention, or a precursor thereto, is made
either by 1) solid-phase synthetic chemistry; 2) purification
of GLP molecules from natural sources; or 3) recombinant DNA
technology.

-14-

Solid phase chemical synthesis of polypeptides is well known in the art and may be found in general texts in the area such as Dugas, H. and Penney, C., *Bioorganic Chemistry*, Springer-Verlag, New York (1981), pp. 54-92, Merrifield, J.M., *Chem. Soc.*, 85:2149 (1962), and Stewart and Young, *Solid Phase Peptide Synthesis*, Freeman, San Francisco (1969) pp. 24-66.

For example, the amino acid portion may be synthesized by solid-phase methodology utilizing a 430A peptide synthesizer (PE-Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster City, CA 94404) and synthesis cycles supplied by PE-Applied Biosystems. BOC-amino acids and other reagents are commercially available from PE-Applied Biosystems and other chemical supply houses. Sequential Boc chemistry using double couple protocols are applied to the starting p-methyl benzhydryl amine resins for the production of C-terminal carboxamides. For the production of C-terminal acids, the corresponding PAM resin is used. Asn, Gln, and Arg are coupled using preformed hydroxy benzotriazole esters. The following side chain protecting groups may be used:

```
Arg, Tosyl
Asp, cyclohexyl
Glu, cyclohexyl
Ser, Benzyl
Thr, Benzyl
Tyr, 4-bromo carbobenzoxy
```

Boc deprotection may be accomplished with trifluoroacetic acid in methylene chloride. Following completion of the synthesis the peptides may be deprotected and cleaved from the resin with anhydrous hydrogen fluoride (HF) containing 10% meta-cresol. Cleavage of the side chain protecting group(s) and of the peptide from the resin is carried out at -5°C to 5°C, preferably on ice for 60 minutes. After removal of the HF, the peptide/resin is washed with ether, and the peptide extracted with glacial acetic acid and lyophilized.

Techniques well-known to the ordinarily-skilled artisan in recombinant DNA technology may be used to prepare

-15-

the active compound used in present invention. In fact,
recombinant DNA methods may be preferable because of higher
yield. The basic steps in recombinant production are:

5   a)   isolating a natural DNA sequence encoding a
                 GLP-1 molecule or constructing a synthetic or
                 semi-synthetic DNA coding sequence for a GLP-1
                 molecule,

10   b)   placing the coding sequence into an expression
                 vector in a manner suitable for expressing
                 proteins either alone or as a fusion proteins,

           c)   transforming an appropriate eukaryotic or
15   prokaryotic host cell with the expression
                 vector,

           d)   culturing the transformed host cell under
                 conditions that will permit expression of a
20   GLP-1 molecule, and

           e)   recovering and purifying the recombinantly
                 produced GLP-1 molecule.

           As previously stated, the coding sequences may be
25   wholly synthetic or the result of modifications to the larger,
      native glucagon-encoding DNA. A DNA sequence that encodes
      preproglucagon is presented in Lund, *et al.*, *Proc. Natl. Acad.*
      Sci. U.S.A. 79:345-349 (1982) and may be used as starting
      material in the semisynthetic production of the compounds of
30   the present invention by altering the native sequence to
      achieve the desired results.

           Synthetic genes, the *in vitro* or *in vivo*
      transcription and translation of which results in the
      production of a GLP-1 molecule, may be constructed by
35   techniques well known in the art. Owing to the natural
      degeneracy of the genetic code, the skilled artisan will
      recognize that a sizable yet definite number of DNA sequences
      may be constructed, all of which encode GLP-1 molecules.

           The methodology of synthetic gene construction is
40   well-known in the art. *See* Brown, *et al.* (1979) *Methods in*
      Enzymology, Academic Press, N.Y., 68:109-151. The DNA
      sequence is designed from the desired amino acid sequence
      using the genetic code, which is easily ascertained by the

-16-

ordinarily-skilled biologist.   Once designed, the sequence itself may be generated using conventional DNA synthesizing apparatus such as the   Model 380A or 380B DNA synthesizers (PE-Applied Biosystems, Inc., 850 Lincoln Center Drive, Foster
5   City, CA 94404).

To express the amino acid portion of a compound used in the present invention, one inserts the engineered synthetic DNA sequence in any one of many appropriate recombinant DNA expression vectors through the use of appropriate restriction
10   endonucleases.   *See generally* Maniatis *et al.* (1989) *Molecular Cloning; A Laboratory Manual*, Cold Springs Harbor Laboratory Press, N.Y., Vol. 1-3. Restriction endonuclease cleavage sites are engineered into either end of the GLP-1 molecule-encoding DNA to facilitate isolation from, and integration
15   into, amplification and expression vectors well-known in the art.   The particular endonucleases employed will be dictated by the restriction endonuclease cleavage pattern of the parent expression vector employed.   Restriction sites are chosen to properly orient the coding sequence with control sequences,
20   thereby achieving proper in-frame reading and expression of the protein of interest.   The coding sequence must be positioned to be in proper reading frame with the promoter and ribosome binding site of the expression vector, both of which are functional in the host cell in which the protein is to be
25   expressed.

To achieve efficient transcription of the synthetic gene, it must be operably associated with a promoter-operator region.   Therefore, the promoter-operator region of the synthetic gene is placed in the same sequential orientation
30   with respect to the ATG start codon of the synthetic gene.

A variety of expression vectors useful for transforming prokaryotic and eukaryotic cells are well known in the art. *See The Promega Biological Research Products Catalogue* (1992) (Promega Corp., 2800 Woods Hollow Road,
35   Madison, WI, 53711-5399); and *The Stratagene Cloning Systems Catalogue* (1992) (Stratagene Corp., 11011 North Torrey Pines Road, La Jolla, CA, 92037).   Also, U.S. Patent No. 4,710,473

-17-

describes circular DNA plasmid transformation vectors useful
for expression of exogenous genes in *E. coli* at high levels.
These plasmids are useful as transformation vectors in
recombinant DNA procedures and

5

       (a)   confer on the plasmid the capacity for autonomous
              replication in a host cell;

       (b)   control autonomous plasmid replication in relation
10   to the temperature at which host cell cultures are
              maintained;

       (c)   stabilize maintenance of the plasmid in host cell
              populations;
15
       (d)   direct synthesis of a protein product indicative of
              plasmid maintenance in a host cell population;

       (e)   provide in-series restriction endonuclease
20   recognition sites unique to the plasmid; and

       (f)   terminate mRNA transcription.

These circular DNA plasmids are useful as vectors in
25 recombinant DNA procedures for securing high levels of
expression of exogenous genes.

       Having constructed an expression vector for the
amino acid portion of a compound used in the present
invention, the next step is to place the vector into a
30 suitable cell and thereby construct a recombinant host cell
useful for expressing the polypeptide. Techniques for
transforming cells with recombinant DNA vectors are well known
in the art and may be found in such general references as
Maniatis, *et al. supra*. Host cells made be constructed from
35 either eukaryotic or prokaryotic cells.

       Prokaryotic host cells generally produce the protein
at higher rates and are easier to culture. Proteins expressed
in high-level bacterial expression systems characteristically
aggregate in granules or inclusion bodies, which contain high
40 levels of the overexpressed protein. Such protein aggregates
typically must be recovered, solubilized, denatured and
refolded using techniques well known in the art. *See* Kreuger,
et al. (1990) in *Protein Folding*, Gierasch and King, eds., pgs

136-142, American Association for the Advancement of Science
Publication No. 89-18S, Washington, D.C.; and U.S. Patent No.
4,923,967.

Alterations to a precursor GLP-1 or GLP-1 analog
5   amino acid sequence, to produce a desired GLP-1 analog or GLP-
1 derivative, are made by well-known methods: chemical
modification, enzymatic modification, or a combination of
chemical and enzymatic modification of GLP-1 precursors. The
techniques of classical solution phase methods and semi-
10   synthetic methods may also be useful for preparing the GLP-1
molecules used in the present invention. Methods for
preparing the GLP-1 molecules of the present invention are
well known to an ordinarily skilled peptide chemist.

Addition of an acyl group to the epsilon amino group
15   of Lys^{34} may be accomplished using any one of a variety of
methods known in the art. See *Bioconjugate Chem.* "Chemical
Modifications of Proteins: History and Applications" pages 1,
2-12 (1990) and Hashimoto *et al.*, *Pharmacuetical Res.*
6(2):171-176 (1989).

20   For example, an N-hydroxy-succinimide ester of
octanoic acid can be added to the lysyl-epsilon amine using
50% acetonitrile in borate buffer. The peptide can be
acylated either before or after the imidazolic group is added.
Moreover, if the peptide is prepared recombinantly, acylation
25   prior to enzymatic cleavage is possible. Also, the lysine in
the GLP-1 derivative can be acylated as taught in WO96-29342,
which is incorporated herein by reference.

The existence and preparation of a multitude of
protected, unprotected, and partially-protected, natural and
30   unnatural, functional analogs and derivatives of GLP-1 (7-
36)amide and GLP-1 (7-37) molecules have been described in the
art [*see, e.g.*, U.S. Pat. No. 5,120,712 and 5,118,666, which
are herein incorporated by reference, and Orskov, C., *et al.*,
J. Biol. Chem., 264(22):12826-12829 (1989) and WO 91/11457
35   (Buckley, D.I., *et al.*, published August 8, 1991)].

Optionally, the amino and carboxy terminal amino
acid residues of GLP-1 derivatives may be protected, or,

-19-

optionally, only one of the termini is protected. Reactions
for the formation and removal of such protecting groups are
described in standard works including, for example,
"Protective Groups in Organic Chemistry", Plenum Press, London
5   and New York (1973); Green, T.H., "Protective Groups in
Organic Synthesis", Wiley, New York (1981); and "The
Peptides", Vol. I, Schröder and Lübke, Academic Press London
and New York (1965). Representative amino-protecting groups
include, for example, formyl, acetyl, isopropyl,
10   butoxycarbonyl, fluorenylmethoxycarbonyl, carbobenzyloxy, and
the like. Representative carboxy-protecting groups include,
for example, benzyl ester, methyl ester, ethyl ester, t-butyl
ester, p-nitro phenyl ester, and the like.

          Carboxy-terminal, lower-alkyl-ester, GLP-1
15   derivatives used in the present invention are prepared by
reacting the desired (C_1-C_4) alkanol with the desired
polypeptide in the presence of a catalytic acid such as
hydrochloric acid. Appropriate conditions for such alkyl
ester formation include a reaction temperature of about 50°C
20   and reaction time of about 1 hour to about 3 hours.
Similarly, alkyl ester derivatives of the Asp and/or Glu
residues can be formed.

          Preparation of a carboxamide derivative of a
compound used in the present invention is formed, for example,
25   as described in Stewart, J. M., et al., *Solid Phase Peptide
Synthesis*, Pierce Chemical Company Press, 1984.

          A pharmaceutically-acceptable salt form of GLP-1,
of a GLP-1 analog, or of a GLP-1 derivative may be used in
the present invention. Acids commonly employed to form acid
30   addition salts are inorganic acids such as hydrochloric
acid, hydrobromic acid, hydroiodic acid, sulfuric acid,
phosphoric acid, and the like, and organic acids such as p-
toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-
bromophenyl-sulfonic acid, carbonic acid, succinic acid,
35   citric acid, benzoic acid, acetic acid, and the like.
Examples of such salts include the sulfate, pyrosulfate,
bisulfate, sulfite, bisulfite, phosphate,

-20-

monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate,
5 malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate,
10 phenylbutyrate, citrate, lactate, gamma-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, and the like. Preferred acid addition salts are those formed with mineral acids such as hydrochloric acid and
15 hydrobromic acid, and, especially, hydrochloric acid.

Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention
20 thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, and the like. The salt forms are particularly preferred.

A GLP-1, GLP-1 analog, or GLP-1 derivative used in the present invention may be formulated with one or more
25 excipients before use in the present invention. For example, the active compound used in the present invention may be complexed with a divalent metal cation by well-known methods. Such metal cations include, for example, Zn^{++}, Mn^{++}, Fe^{++}, Co^{++}, Cd^{++}, Ni^{++}, and the like.
30 Optionally, the active compound used in the present invention may be combined with a pharmaceutically-acceptable buffer, and the pH adjusted to provide acceptable stability, and a pH acceptable for parenteral administration.

Optionally, one or more pharmaceutically-acceptable
35 anti-microbial agents may be added. Meta-cresol and phenol are preferred pharmaceutically-acceptable anti-microbial agents. One or more pharmaceutically-acceptable salts may be

-21-

added to adjust the ionic strength or tonicity. One or more
excipients may be added to further adjust the isotonicity of
the formulation. Glycerin is an example of an isotonity-
adjusting excipient.

5   Administration may be via any route known to be
effective by the physician of ordinary skill. Parenteral
administration is preferred. Parenteral administration is
commonly understood in the medical literature as the injection
of a dosage form into the body by a sterile syringe or some
10   other mechanical device such as an infusion pump. Parenteral
routes include intravenous, intramuscular, subcutaneous,
intraperitoneal, intraspinal, intrathecal,
inracerebroventricular, intraarterial, subarachnoid, and
epidural. Intravenous, intramuscular, and subcutaneous routes
15   of administration of the compounds used in the present
invention are more preferred. Intravenous and subcutaneous
routes of administration of the compounds used in the present
invention are yet more highly preferred. For parenteral
administration, an active compound used in the present
20   invention preferably is combined with distilled water at an
appropriate pH.

         Additional pharmaceutical methods may be employed to
control the duration of action. Controlled release
preparations may be achieved by the use of polymers to complex
25   or absorb the active compound used in the present invention.
Extended duration may be obtained by selecting appropriate
macromolecules, for example, polyesters, polyamino acids,
polyvinylpyrrolidone, ethylenevinyl acetate, methylcellulose,
carboxymethylcellulose, or protamine sulfate, and by selecting
30   the concentration of macromolecules, as well as the methods of
incorporation, in order to prolong release. Another possible
method to extend the duration of action by controlled release
preparations is to incorporate an active compound used in the
present invention into particles of a polymeric material such
35   as polyesters, polyamino acids, hydrogels, poly (lactic acid)
or ethylene vinylacetate copolymers. Alternatively, instead
of incorporating a compound into these polymeric particles, it

-22-

is possible to entrap a compound used in the present invention in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules, respectively,
5   or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules, or in macroemulsions. Such teachings are disclosed in *Remington's Pharmaceutical Sciences* (1980).

          According to the teachings of this invention, a
10 patient is in need of the compounds used in the present invention for about 1-16 hours before surgery is performed on said patient, during surgery on said patient, and after said patient's surgery for a period of not more than about 5 days.

          As mentioned above, the length of time before
15 surgery to begin to administer the compounds used in the present invention is from about sixteen hours to about one hour before surgery begins. The length of time before surgery when the compounds used in the present invention should be administered in order to reduce catabolic effects and insulin
20 resistance will depend on factors whose effects are known to the physician of ordinary skill, and include, most importantly, whether the patient is fasted or supplied with a glucose infusion or beverage, or some other form of sustenance during the preparatory period before surgery, and also,
25 without limitation, the patient's sex, weight and age, the severity of any inability to regulate blood glucose, the underlying causes of any inability to regulate blood glucose, the expected severity of the trauma caused by the surgery, the route of administration and bioavailability, the persistence
30 in the body, the formulation, and the potency of the compound administered. A preferred time interval within which to begin administration of the compounds used in the present invention is from about one hour to about ten hours before surgery begins. The most preferred interval to begin administration
35 is between two hours and eight hours before surgery begins.

          As explained hereinabove, insulin resistance following a particular type of surgery, elective abdominal

-23-

surgery, is most profound on the first post-operative day,
lasts at least five days, and may take up to three weeks to
normalize [Thorell, A., et al., (1993)]. Thus, the post-
operative patient may be in need of administration of the
5   compounds used in the present invention for a period of time
following the trauma of surgery that will depend on factors
that the physician of ordinary skill will comprehend and
determine. Among these factors are whether the patient is
fasted or supplied with a glucose infusion or beverage, or
10 some other form of sustenance following surgery, and also,
without limitation, the patient's sex, weight and age, the
severity of any inability to regulate blood glucose, the
underlying causes of any inability to regulate blood glucose,
the actual severity of the trauma caused by the surgery, the
15 route of administration and bioavailability, the persistence
in the body, the formulation, and the potency of the compound
administered. The preferred duration of administration of the
compounds used in the present invention is not more than five
days following surgery.

20   The term "post-surgical catabolic changes" is well-
known to the surgeon of ordinary skill [Shaw, J.H.F., et al.,
Ann. Surg. (1989); Little, R. A., et al. (1987); Frayn, K.N.
(1986); Brandi, L., et al., (1993)], and is defined herein as
a state of metabolism caused by the trauma of surgery that may
25 be characterized by one or more of the following phenomena:
negative nitrogen balance, with loss of body nitrogen
[Wernerman, J., et al., J. Parent. Enter. Nutr. 10:578-82
(1986); Tashiro, T., et al., J. Parent. Enter. Nutr. 9:452-5
(1985)], peripheral utilization of fat in preference to
30 glucose with reduction of the respiratory quotient [Frayn,
K.N., et al., Arch. Emerg. Med. 4:91-9 (1987); Stjernstrom,
H., et al., Clin. Physiol. 1:59-72 (1981)], and endogenous
glucose production at the expense of body protein and energy
stores in spite of hyperglycemia [Gump, F.E., et al., (1974);
35 Black, R.B., et al., (1982); Frayn, K.N., et al., (1987);
Frayn, K.N. Br. Med. Bull. 41(3):232-9 (1985)].

-24-

        The term "insulin resistance" is also well-known to
physicians of ordinary skill, and is defined herein as a
physiological condition wherein normal concentrations of
insulin elicit less than normal responses. Insulin resistance
5   may be due to a decrease in binding of insulin to cell-surface
receptors, or to alterations in intracellular metabolism. The
first type, characterized as a decrease in insulin
sensitivity, can typically be overcome by increased insulin
concentration. The second type, characterized as a decrease
10 in insulin responsiveness, cannot be overcome by large
quantities of insulin. Insulin resistance following trauma
can be overcome by doses of insulin that are proportional to
the degree of insulin resistance, and thus is apparently
caused by a decrease in insulin sensitivity [Brandi, L.S., *et
15 al., Clin. Science* 79:443-450 (1990); Henderson, A.A., *et al.,
Clin. Sci.* 80:25-32 (1990)]. Reduction in insulin sensitivity
following elective abdominal surgery lasts at least five days,
but not more than three weeks, and is most profound on the
first post-operative day, and may take up to three weeks to
20 normalize [Thorell, A., *et al.,* (1993)]. The causes of the
observed transient insulin resistance following trauma are not
well-understood.

        The dose of GLP-1, GLP-1 analog, or GLP-1 derivative
effective to normalize a patient's blood glucose level will
25 depend on a number of factors, among which are included,
without limitation, the patient's sex, weight and age, the
severity of inability to regulate blood glucose, the
underlying causes of inability to regulate blood glucose,
whether glucose, or another carbohydrate source, is
30 simultaneously administered, the route of administration and
bioavailability, the persistence in the body, the formulation,
and the potency. Where administration is continuous, a
suitable dosage rate is between 0.25 and 6 pmol/kg body
weight/min, preferably from about 0.5 to about 1.2
35 pmol/kg/min. Where administration is intermittent, the dose
per administration should take into account the interval
between doses, the bioavailability of GLP-1, GLP-1 analog, or

-25-

GLP-1 derivative, and the level needed to effect normal blood glucose. It is within the skill of the ordinary physician to titrate the dose and rate of administration of GLP-1, GLP-1 analog, or GLP-1 derivative to achieve the desired clinical
5   result.

The present invention will be more readily understood by reference to specific examples, which are provided to illustrate, not to limit, the present invention.

10   Example 1

Thirteen patients, scheduled for elective orthopedic surgery (hipartroplasty), participated in the study. None of the patients had any history or signs of metabolic disease, liver affection, or diabetes mellitus. Fasting blood glucose
15   levels, CRP and liver tests (bilirubine, alkaline phosfatase, AST and ALT) were normal in all thirteen patients.

Seven patients (*insulin* group, age, 56±5 years; BMI, 25±1 kg/m^2) were studied beginning at 08:00 after an overnight fast. After an initial basal period, during which time
20   samples were taken for measurements of blood glucose and hormones, and indirect calorimetry was performed for 30 min, insulin (Actrapid®, Novo, Copenhagen) was infused intravenously at a constant rate of 0.8 mU/kg/min, while a variable intravenous infusion of glucose (200 mg/ml) was given
25   to maintain blood glucose at a constant level (4.5 mM). After one hour at steady state conditions, all patients underwent a standardized surgical treatment (hipartroplasty). The operation started 290±23 minutes after the beginning of insulin infusion. The hyperinsulinemic, normoglycemic clamp
30   was then maintained during surgery and continued for a further 3-4 hours after surgery. The data will be presented according to the following nomenclature:

basal   30 min. before start of insulin
          infusion
35   *preop clamp*   steady state hyperinsulinemic,
          normoglycemic clamp for 60 min before
          surgery

> *early op*   from 10 to 40 min. after the
>   initiation of surgery
> *late op*   the last 30 min. of surgery
> *postop clamp*   steady state hyperinsulininemic,
>   normoglycemic clamp for 60 min.,
>   starting 143±30 min after the
>   initiation of surgery.

A second group of patients *(control* group, n = 6, age, 59±3 years; BMI, 26±1 kg/m²), matched to the *insulin* group with regard to age and BMI, received the same preoperative protocol *(basal* and *preop* clamp) seven days before surgery. The control group received no basal or preop clamp on the day of surgery. However, immediately surgery, each patient in the control group received infusion of insulin (0.8 mU/kg/min.), and a hyperinsulinemic, normoglycemic (4.5 mM) clamp *(postop)* was begun.

Indirect calorimetry (Deltatrac® Dansjöö, Sweden) [Frayn, K.N. *J. Appl. Physiol.* 55(2):628-34 (1983); Takala, J., et al., *Crit. Care Med.* 17(10): 1041-47 (1989)] was performed for 30 minutes during the *basal* phase, twice during surgery *(early op* and *late op)*, and during the last 30 minutes of the *preop* and *postop* clamps. Timed sampling of urine for analysis of urinary urea excretion was performed. After correction for changes in urea pool size [Tappy, L, et al., *Diabetes* 37:1212-16 (1988)], non-protein energy expenditure (EE), respiratory quotients (RQ) and substrate oxidation rates were calculated.

Blood samples were collected from a heated hand vein repeatedly during the *basal, preop, early op, late op and postop* periods. Blood glucose was measured immediately upon collection using the glucose oxidase method (Yellow Springs Instruments, Yellow Springs, Ohio) [Hugget, A.S., et al., *Lancet* 2:368-70 (1957)]. Radio immunoassays (RIA) were used to measure serum concentrations of insulin [Grill, V., et al., *Metabolism* 39:251-58 (1990)]; C-peptide (Novo Research, Bagsværd, Denmark); cortisol [Harris, V., et al., *In Jaffe,*

-27-

B.M. & Behrman, H.R., eds. *Methods of hormone radioimmunoassay*, Academic Press, New York and London (1979) pp. 643-56]; and glucagon (Euro-Diagnostica AB, Malmö, Sweden) [Faloona, G.R., *et al., Glucagon radioimmunoassay technique.*

5 Vol. 1: Academic Press, New York (1974)].

All values are individual values, or mean±SEM (standard error of the mean). Statistical significance is accepted at $p<0.05$ using Wilcoxon's signed rank test and the Mann-Whitney U-test for paired and unpaired data respectively.

10 Because serum insulin levels at the *postop* clamp tended to be lower in the control group compared to the insulin group ($p=0.06$), GIR during clamps were also corrected to the prevailing insulin levels by dividing GIR and the mean serum insulin level during the 60 minute steady-state periods.

15 Serum insulin levels were similar between the two groups, both at basal and during the *preop* clamp. In the *insulin* group, insulin levels remained around 60 μU/ml during surgery and the *postop* clamp. In the *control* group, insulin levels remained unchanged compared to *basal* levels during

20 surgery. Insulin levels at the *postop* clamp in the *control* group were not significantly different from the levels during the *preop* clamp nor different to those in the *insulin* group during *the postop* clamp.

C-peptide levels (Table I) were similar between the

25 groups at *basal* and during the *preop* and *postop* clamps. The *insulin* group displayed lower C-peptide levels during surgery compared to the *control* group.

Serum glucagon levels decreased ($p<0.05$) after surgery in both groups (Table I). However, the relative

30 change after surgery (% vs preop) was higher in the *insulin* group ($p<0.01$ vs *control*).

Serum cortisol levels (Table I) decreased after surgery in the *insulin* group while levels in the *control* group tended to increase ($p=0.1$). The postoperative levels of

35 cortisol were lower in the *insulin* group compared to the *control* group ($p<0.05$).

Table I. Hormone levels in patients undergoing hipartroplasty
          after an overnight fast (control, n=6), or after
          four hours of physiological hyperinsulinemia
          (insulin, n=7).

	basal	pre op	early op	late op	post op
C-peptide					
control	.68±.08	.41±.09	.70±.11	.70±.13	.31±.09
insulin	.68±.09	.45±.05	.42±.06[†]	.58±.12	.52±.11
Glucagon					
control	48±2	42±1	43±3	41±3	37±2[*]
insulin	58±7	52±3[†]	40±3	35±4	33±4[*]
Cortisol					
control	229±39	238±21	154±63	116±43	366±83[*]
insulin	171±41	266±35	234±46	212±44	172±83[†*]

[*]$p<0.05$ compared to preop by the Wilcoxon signed rank test;
[†]$p<0.05$ compared to control by the Mann-Whitney U-test.

Glucagon levels decreased in both groups after
surgery although the greatest reduction (%) was found in the
insulin group ($p<0.01$ vs control). Cortisol levels decreased
after surgery in the insulin group ($p<0.05$ vs preop), while
levels in the control group tended to increase ($p = 0.1$).
Thus, cortisol levels were significantly lower in the insulin
group compared to the control group after surgery ($p<0.05$).

Glucose infusion rates (GIRs) were not significantly
different between the insulin and control groups during the
preop clamp. The control group had a decreased average GIR
required to maintain normoglycemia during the postop clamp
compared to the preop clamp (-39±5%, $p<0.05$). In contrast,
the insulin group maintained the GIR during surgery, and, on
average, even tended to increase GIR in the postop clamp
(+16±20%, $p=0.2$). Most significantly, and unexpectedly, the
average GIR during the postop clamp in the insulin group was
significantly higher compared to the control group ($p<0.05$)
(see Figure 1). All changes in GIR at the preop and postop
clamps were statistically significant ($p<0.05$), regardless of
whether GIR was corrected for the mean serum insulin levels
during the periods of steady state.

-29-

Glucose and fat oxidation rates were similar between the groups before surgery. During surgery, glucose oxidation rates were significantly higher, while fat oxidation rates were significantly lower in the *insulin* group ($p<0.05$ vs.
5   *control*). At the *postop* clamp, no change in substrate oxidation rates could be found in the *insulin* group as compared to the *preop* clamp. Resting energy expenditure (EE) did not differ between the groups during or after surgery, and remained the same in both groups after surgery as compared to
10 the *preop* clamp.

Fasting glucose levels were similar between the *insulin* and *control* groups. At steady-state during insulin infusion, normoglycemia was maintained, resulting in mean intra-individual coefficients of variation for glucose of 4.6%
15 in the *control*, and 6.2% in the *insulin* group.

These findings conclusively demonstrate that patients undergoing elective surgery in the fasted state develop postoperative insulin resistance and increased fat oxidation. Furthermore, these findings also demonstrate for
20 the first time that catabolic changes after surgery are completely abolished, and the hormonal response to stress completely attenuated, if the patients enter surgical stress in a state of elevated insulin levels which is maintained throughout the operation.
25

Example 2

GLP-1 (7-36) amide was administered by a subcutaneous infusion at a dose rate of 1.2 pmol/kg/hr, for ten hours during the night, to five patients having non-
30 insulin dependent diabetes (NIDDM). As a control, insulin was continuously infused in the same five patients, but on a different day than the GLP-1 (7-36) amide infusion. The rate of insulin infusion was adjusted every two hours to achieve optimum control, and to avoid hypoglycemia. As demonstrated
35 by the data in Table II, and in Figure 2, subcutaneous infusion of GLP-1 (7-36) amide nearly normalized blood glucose without inducing hypoglycemia in any of the patients. The

metabolic control with GLP-1 (7-36) amide was better than that
achieved by insulin, and the average blood glucose level was
lower for GLP-1 (7-36) amide treatment than for the control by
a statistically significant amount at 23:00, 0:00, and at
5   1:00.

       Table II. Average blood glucose levels for five NIDDM patients
                  continuously infused for ten hours during the night
                  with GLP-1 (7-36) amide.   In a control study with
10   the same patients on a different day, insulin was
                  administered by continuous infusion.

	GLP-1 Infusion		Insulin Infusion (Control)	
Hour	Average Blood Glucose (mM)	Std. Error (mM)	Average Blood Glucose (mM)	Std. Error (mM)
21:00	7.5	0.45	6.9	0.68
22:00	5.4	0.76	6.6	0.55
23:00	4.3	0.16	5.9	0.98
0:00	4.4	0.23	5.6	0.90
1:00	4.4	0.29	5.1	0.58
2:00	4.8	0.34	5.2	0.58
3:00	5.2	0.41	5.4	0.30
4:00	5.4	0.41	5.7	0.25
5:00	5.8	0.41	6.0	0.30
6:00	6.0	0.45	6.1	0.38
7:00	6.2	0.45	6.1	0.33

-31-

Example 3

During the day, GLP-1 (7-36) amide was infused into
five NIDDM patients for three hours during breakfast, lunch,
and dinner. The infusion times were 7:30-10:30 (breakfast),
5   10:30-1:30 (lunch), and 4:30-7:30 (dinner), as indicated in
Figure 3. In a control experiment in the same five NIDDM
patients conducted on a different day, insulin was injected
subcutaneously just before the start of the meals, as
indicated in Figure 3. While GLP-1 was infused, the post-
10 prandial glucose excursions observed with insulin injection
were eliminated, and normal blood glucose levels were
maintained. Immediately after terminating each GLP-1 (7-36)
amide infusion, the blood glucose level increased
significantly. No untoward side effects of GLP-1 (7-36) amide
15 were observed. These data indicate that GLP-1 (7-36) amide
infusion more effectively controls post-prandial glucose
levels than insulin injection, and that the control is
effective as long as GLP-1 (7-36) amide infusion is continued.

-32-

Table III. Average blood glucose levels for five NIDDM
patients infused with GLP-1 (7-36) amide for three
hours, beginning at the start of each meal. In a
control study with the same patients on a different
day, insulin was administered by subcutaneous
injection just before each meal. Meals began at
7:30, 10:30, and at 4:30.

Hour	GLP-1 Infusion		Insulin Subcutaneous Injection	
	Average Blood Glucose (mM)	Std. Error (mM)	Average Blood Glucose (mM)	Std. Error (mM)
7:00	5.4	0.35	6.1	0.41
8:00	4.9	0.38	7.0	0.51
9:00	5.7	0.59	9.1	0.74
10:00	5.8	1.06	9.9	0.78
11:00	8.1	0.94	8.2	0.76
12:00	9.4	0.59	6.5	0.74
13:00	7.2	1.18	9.1	0.90
14:00	5.3	1.21	8.1	0.91
15:00	7.2	0.71	7.0	0.87
16:00	10.4	0.26	7.2	0.57
17:00	9.2	1.06	6.5	0.59
18:00	5.7	1.59	7.3	0.65
19:00	6.6	0.94	6.1	0.59
20:00	8.3	0.71	6.0	0.41
21:00	9.3	0.71	6.4	0.44

-33-

I claim:

1.   A method of attenuating post-surgical catabolic changes and insulin resistance, comprising, administering to a patient in need thereof a compound selected from the group
5   consisting of GLP-1, GLP-1 analogs, GLP-1 derivatives, and pharmaceutically-acceptable salts thereof.

2.   The method of Claim 1, wherein the compound is administered intravenously.

3.   The method of Claim 1, wherein the compound is
10   administered subcutaneously.

4.   The method of Claims 2 or 3, wherein the administration is continuous.

5.   The method of Claim 4 wherein the rate of administration of the compound is between 0.25 and 6
15   pmol/kg/min.

6.   The method of Claim 5 wherein the rate of administration of the compound is between 0.5 and 2.4 pmol/kg/min.

7.   The method of Claim 5 wherein said rate is
20   between about 0.5 and about 1.2 pmol/kg/min.

8.   The method of Claim 2 wherein the intravenous administration is intermittent.

9.   The method of Claim 2 wherein the compound is administered intravenously and also administered by another
25   parenteral route.

10.   The method of Claim 9 wherein the other parenteral route is the subcutaneous route.

11.   The method of Claim 1 wherein the compound administered is GLP(7-36) amide, or a pharmaceutically-
30   acceptable salt thereof.

12.   A method of attenuating post-surgical catabolic changes and hormonal responses to stress, comprising, administering to a patient in need thereof a compound that exerts insulinotropic activity by interacting with the same
35   receptor, or receptors, with which GLP-1, GLP-1 analogs, and GLP-1 derivatives interact in exerting their insulinotropic activity.

    13.   A method of attenuating post-surgical catabolic changes and hormonal responses to stress, comprising, administering a compound that enhances insulin sensitivity by interacting with the same receptor, or receptors, with which
5 GLP-1, GLP-1 analogs, and GLP-1 derivatives interact to enhance insulin sensitivity.

Fig. 1

FIG. 2

FIG. 3

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6)   :C07K 14/605, 14/00; A61K 38/00, 38/26
US CL   :514/12; 530/300, 308, 399
According to International Patent Classification (IPC) or to both national classification and IPC

B.   FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C.   DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database Medline on STN, US National Library of Medicine, (Bethesda, MD, USA), No. 88166193, SACHS et al. '[Postaggression metabolism following laparotomy and thoracotomy]. Untersuchungen uber den Postaggressionsstoffwechsel nach Laparotomien und Thoracotomien,' abstract, CHIRURG, January 1988, Vol. 59, No. 1, pages 24-33.	1-13
Y	GUTNIAK et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. The New England Journal of Medicine. 14 May 1992, Vol. 326, pages 1316-1322, especially page 1316.	1-13

[X] Further documents are listed in the continuation of Box C.   [ ] See patent family annex.

	Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
03 OCTOBER 1997	2 8 NOV 1997

Name and mailing address of the ISA/US	Authorized officer
Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	DAVID S. ROMEO
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

International application No.

PCT/US97/15042

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MIZOCK, B.A. Alterations in carbohydrate metabolism during stress: A review of the literature. The American Journal of Medicine. January 1995, Vol. 98, pages 75-84, especially pages 75 and 81-82.	1-13
Y	DEACON et al. Both subcutaneously and intravenously administered glucagon-like peptide-I are rapidly degraded from the NH_2-terminus in type II diabetic patients and in healthy subjects. Diabetes. September 1995, Vol. 44, pages 1126-1131, especially page 1127.	2, 3, 5-7
A	LUND et al. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequencing arranged in tandem. Proc. Natl. Acad. Sci. USA. January 1982, Vol. 79, pages 345-349.	1, 11, 12, 13
Y	WO 91/11457 A1 (BUCKLEY et al.) 08 August 1991 (08.08.91), pages 4-7.	1-13

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, Medline
search terms: surgery, surgical, trauma, glucose, metabolism, metabolic, catabolism, catabolic, insulin resistance, glucagon like peptide, glp, glucagon, stress diabetes, surgical diabetes.